Press Releases

Date Title and Summary
Toggle Summary Webcast Alert: Isis Pharmaceuticals, Inc. Presentation at Informed Investors Security and Defense Virtual Stocks Forum to be Webcast on Thursday, July 29, 2004, 11:00 am ET
Toggle Summary Isis Pharmaceuticals Earns $1 Million Milestone Payment From Eyetech Related to Filing of Macugen(TM) New Drug Application
Toggle Summary Isis Pharmaceuticals to Present at Third Annual Needham Biotechnology Conference
Toggle Summary Isis Gains Full Ownership of Orasense(TM) and HepaSense(TM) Subsidiaries and Eliminates Future Royalty Payments to Elan
Toggle Summary Second-Generation Antisense Inhibitors Provide New Insights Into Metabolic Disease and Potential Treatments
Toggle Summary Antisense Therapeutics Limited and Isis Pharmaceuticals Announce Positive Results From a Phase 1 Trial of ATL-1102 for Multiple Sclerosis
Toggle Summary OncoGenex and Isis Pharmaceuticals Announce Compelling Data from Phase I Prostate Cancer Study at ASCO Annual Meeting
Toggle Summary Webcast Alert: Isis Pharmaceuticals to Provide General Corporate Update in Conjunction with 2004 Annual Meeting of Stockholders
Toggle Summary Isis Pharmaceuticals Announces Extension of Antisense Cancer Drug Discovery Collaboration With Lilly
Toggle Summary Isis Pharmaceuticals Reports Financial Results and Highlights for the First Quarter 2004
Toggle Summary Webcast Alert: Isis Pharmaceuticals Announces 2004 First Quarter Financial Results Webcast
Toggle Summary Antisense Drug Demonstrates Potential to Treat Progressive Form of ALS
Toggle Summary Webcast Alert: Isis Pharmaceuticals Announces Strategic Alliance With Alnylam
Toggle Summary Isis Pharmaceuticals Forms Strategic Alliance With Alnylam Pharmaceuticals in RNAi Therapeutics
Toggle Summary Isis Pharmaceuticals' Ibis Program Awarded Government Contract for Up to $19.5 Million for Continued Development of TIGER Biosensor for Biological Warfare Defense
Toggle Summary Isis Pharmaceuticals Reports Financial Results and Highlights for 2003
Toggle Summary Webcast Alert: Isis Pharmaceuticals Announces 2003 Financial Results Webcast
Toggle Summary Isis Pharmaceuticals Identifies SARS Antisense Drug Candidates Through Collaboration with ITRI of Taiwan
Toggle Summary Isis Pharmaceuticals Reports Positive Data from Phase 2 Trial Of ISIS 104838 in Rheumatoid Arthritis
Toggle Summary Webcast Alert: Isis Pharmaceuticals Announces Phase 2 Results of ISIS 104838 in Rheumatoid Arthritis
Toggle Summary Isis Pharmaceuticals Initiates Phase I Study of Second-Generation Antisense Drug for Cardiovascular Disease
Toggle Summary Isis Pharmaceuticals Retires $32 Million in Convertible Partner Debt With Low-Interest Five-Year Loan
Toggle Summary Antisense Drug Targeting Survivin Inhibits Growth Of Tumors In Animal Models
Toggle Summary Isis Pharmaceuticals Reports Third Quarter 2003 Highlights And Financial Results
Toggle Summary Isis Pharmaceuticals Broadens Micro-RNA Drug Discovery Program With Support From Singapore Economic Development Board
Toggle Summary Webcast Alert: Isis Pharmaceuticals Announces Third Quarter Financial Results Webcast
Toggle Summary Isis Pharmaceuticals Updates Positive Clinical Data on Multiple Antisense Drugs
Toggle Summary Isis Pharmaceuticals' Ibis Program Receives $6 Million Grant from the CDC for Infectious Disease Surveillance
Toggle Summary Second-Generation Antisense Drug ISIS 104838 Reduces TNF-alpha In Rheumatoid Arthritis Patients
Toggle Summary Second-Generation Type 2 Diabetes Antisense Drug Improves Glucose Tolerance Tests in Normal Volunteers in Phase 1 Study
Toggle Summary OncoGenex Technologies and Isis Pharmaceuticals Expand Antisense Anti-Cancer Drug Development Collaboration
Toggle Summary Antisense Therapeutics Limited and Isis Pharmaceuticals Initiate Phase I Trial of Antisense Drug for Multiple Sclerosis
Toggle Summary Isis Pharmaceuticals Reports Second Quarter 2003 Highlights and Financial Results
Toggle Summary Webcast Alert: Isis Pharmaceuticals Announces Second Quarter Financial Results Webcast
Toggle Summary Isis Pharmaceuticals and ITRI of Taiwan Initiate SARS Antisense Drug Discovery Effort
Toggle Summary Webcast Alert: Isis Pharmaceuticals to Provide General Corporate Update In Conjunction With 2003 Annual Meeting of Shareholders
Toggle Summary Isis Pharmaceuticals and Eli Lilly and Company Renegotiate Affinitak(TM) Manufacturing Relationship
Toggle Summary Isis Pharmaceuticals Provides Summary of American Society of Clinical Oncology Data Presentations on Anti-Cancer Antisense Drugs in Development
Toggle Summary Isis Pharmaceuticals Initiates Phase II Clinical Trial of ISIS 14803 in Patients with Hepatitis C
Toggle Summary Alicaforsen (ISIS 2302) Improves Clinical Symptoms of Pouchitis Patients
Toggle Summary Isis Pharmaceuticals and Ercole Biotech Initiate Collaboration to Create Antisense Drugs Which Control Alternative Splicing
Toggle Summary Isis Pharmaceuticals Initiates Phase I Clinical Trial of Second-Generation Antisense Drug ISIS 113715 for Type 2 Diabetes
Toggle Summary Isis Pharmaceuticals Reports Financial Results And Highlights for the First Quarter 2003
Toggle Summary Webcast Alert: Isis Pharmaceuticals Announces First Quarter Financial Results Webcast
Toggle Summary Isis Pharmaceuticals Achieves Milestone in Antisense Drug Discovery Collaboration With Eli Lilly and Company
Toggle Summary Isis Pharmaceuticals Initiates Additional Phase II Clinical Trial Of Alicaforsen, ISIS 2302, In Patients With Ulcerative Colitis
Toggle Summary Isis Pharmaceuticals Updates Operating Plan For 2003
Toggle Summary Isis Pharmaceuticals Announces Live Webcast to Provide General Corporate Update
Toggle Summary Isis Pharmaceuticals and Eli Lilly and Company Announce Results of Affinitak(TM) Phase III Clinical Trial in Non-Small Cell Lung Cancer
Toggle Summary Reminder - Webcast Alert: Isis Conference Call
Toggle Summary Isis Pharmaceuticals Reports Financial Results and Highlights for the Year 2002
Toggle Summary Isis Pharmaceuticals Earns Second Milestone in Amgen Antisense Drug Discovery Collaboration
Toggle Summary Webcast Alert: Isis Conference Call
Toggle Summary Isis Pharmaceuticals Enters Into Target Validation Agreement With Pfizer
Toggle Summary Isis Pharmaceuticals and atugen AG Enter Patent License Agreement
Toggle Summary Isis Pharmaceuticals Reacquires ISIS 113715 Type 2 Diabetes Drug from Merck
Toggle Summary Isis Pharmaceuticals Reports New Data From Phase II Clinical Trial Of ISIS 2503 Plus Chemotherapy in Pancreatic Cancer
Toggle Summary OncoGenex Technologies and Isis Pharmaceuticals Achieve Alliance Milestone: Initiate Phase I Clinical Trial of Antisense Drug in Prostate Cancer
Toggle Summary Isis Pharmaceuticals and GlaxoSmithKline Enter Into Target Validation Agreement
Toggle Summary Isis Pharmaceuticals Statement Regarding UBS Warburg Report
Toggle Summary Isis Pharmaceuticals Initiates Phase II Clinical Trial of Alicaforsen, ISIS 2302, in Patients With Ulcerative Colitis
Toggle Summary New Data on Capsule Form of ISIS 104838 Demonstrate Antisense Drugs Can Be Administered Orally Orasense Joint Venture Makes Fundamental Advance in Antisense Technology
Toggle Summary Isis Pharmaceuticals and Elan Corporation Conclude Collaboration In HepaSense Joint Venture and Restructure OraSense Collaboration
Toggle Summary Isis Pharmaceuticals Reports Third Quarter And Year-To-Date 2002 Financial Results
Toggle Summary Webcast Alert: Isis Conference Call
Toggle Summary New Phase II Data Confirm ISIS 14803 Produces Significant Viral Level Reductions in Patients With Drug-Resistant Hepatitis C
Toggle Summary Webcast Alert: Isis Conference Call
Toggle Summary Alicaforsen (ISIS 2302) Improves Potential for Responses and Remissions
Toggle Summary Isis Pharmaceuticals to Manufacture Affinitac™ for Eli Lilly and Company
Toggle Summary Isis Receives 1,000th Patent
Toggle Summary Isis Pharmaceuticals and Sequitur Settle Patent Infringement Lawsuit; Sequitur Licenses Isis' Intellectual Property for Functional Genomics
Toggle Summary Isis Pharmaceuticals and Hybridon Cancel Remaining Reciprocal Financial Obligations From Intellectual Property Transaction
Toggle Summary Isis Pharmaceuticals Achieves Milestone In Amgen Antisense Drug Discovery Collaboration
Toggle Summary Isis Pharmaceuticals Reports Second Quarter 2002 Highlights and Financial Results
Toggle Summary Isis Pharmaceuticals Discusses Second Quarter Financial Results
Toggle Summary Isis Pharmaceuticals Continues to Strengthen Balance Sheet by Prepaying $19.7 Million of 12% Convertible Debt Held By Elan
Toggle Summary Webcast Alert: Isis Pharmaceuticals, Inc. Discusses Debt Retirement Progress On the Web; Live and Archived Conference Call Notification
Toggle Summary Isis Pharmaceuticals Initiates European Phase III Clinical Trial Of Alicaforsen, ISIS 2302, in Crohn's Disease
Toggle Summary Isis and Lilly Broaden Antisense Alliance To Include Discovery of Cancer Treatments
Toggle Summary Spencer R. Berthelsen, M.D., F.A.C.P., Elected to Isis Pharmaceuticals' Board of Directors
Toggle Summary Webcast Alert: Isis Pharmaceuticals, Inc. Open House Presentation
Toggle Summary Issuance of Pivotal Patent Provides Isis Pharmaceuticals Therapeutic Control Over Third-Generation Antisense Chemistry
Toggle Summary Isis Pharmaceuticals Expands Therapeutic Potential of Antisense Technology To Cardiovascular Disease
Toggle Summary New Affinitac(TM) Data in Non-Small Cell Lung Cancer Presented at ASCO
Toggle Summary Isis Pharmaceuticals Achieves $3.75 Million Development Milestone In HepaSense Joint Venture With Elan Corporation
Toggle Summary Isis Pharmaceuticals Announces Pricing of Convertible Subordinated Notes
Toggle Summary Isis Pharmaceuticals to Make Early Payment of $74 Million of 14% Senior Subordinated Debt
Toggle Summary Isis Pharmaceuticals Announces Convertible Debt Offering
Toggle Summary Isis Pharmaceuticals Reports First Quarter 2002 Highlights and Financial Results
Toggle Summary Webcast Alert: Isis Pharmaceuticals, Inc. to Discuss Its 2002 First Quarter Financial Results on the Web; Live and Archived Conference Call Notification
Toggle Summary Isis Pharmaceuticals and Merck Extend Hepatitis C Drug Discovery Collaboration for a Second Time
Toggle Summary Isis Pharmaceuticals Reports Preliminary Phase II Data On ISIS 2503 Plus Chemotherapy in Pancreatic Cancer
Toggle Summary Isis Pharmaceuticals' Ibis Therapeutics Division Awarded New $2.4 Million Government Contract to Advance Its Antibacterial Drug Discovery Program
Toggle Summary Issuance of Key Second-Generation Antisense Patent Further Strengthens Isis' Intellectual Property Estate
Toggle Summary Isis Pharmaceuticals Announces Adoption of Securities Trading Plan Under SEC Rule 10b5-1
Toggle Summary Isis Pharmaceuticals' GeneTrove Division Enters Into Target Validation Collaboration and Patent License Agreement With Pharmacia Corporation
Toggle Summary HepaSense Initiates Phase II Clinical Trial of ISIS 14803 in Hepatitis C
Toggle Summary Isis Pharmaceuticals Initiates Phase II Clinical Trial of ISIS 104838, A TNF-Alpha Inhibitor, in Rheumatoid Arthritis
Toggle Summary Dr. John C. Reed Elected to Isis Pharmaceuticals' Board of Directors
Toggle Summary Isis Pharmaceuticals Reports Phase II Study Results Of Topical Alicaforsen, ISIS 2302, in Psoriasis
©1999 - 2017 Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.